Tagged with MSD

Turkey After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence of chronic disease, strong national immunization program and increasing life expectancy. Its general manager for the Turkey cluster, Gözde Güllüoğlu,…

Denmark Long established as a premier early launch country for innovative medicines within Europe, the Danish market access system has become more complicated of late as the Danish Medicines Council – the body charged with providing guidance about new medicines for use in the Danish hospital sector – adjusts to the…

Denmark MSD’s Catherine Williams, a recent arrival in Copenhagen, gives her first impressions of the Danish healthcare system and pharma market, drawing on experiences in her native UK to compare the two countries’ market access environments for innovative products. Williams also touches on MSD’s sizeable clinical trial footprint in Denmark, the…

Singapore One of the main supporting pillars of Singapore’s pharmaceutical industry is its magnificent manufacturing base. Not only does the city-state rank as one of the few countries on the planet that manages to export more medicaments than it imports, but it also plays host to over 50 pharmaceutical manufacturing facilities,…

Ireland The Top 10 pharma companies in Ireland, ranked by annual turnover in The Irish Times Top 1000 list for 2021. Dublin-headquartered Allergan tops the list, followed by global giants MSD, Pfizer, and Gilead. Made with Visme Infographic Maker

China MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its strategically important China business. van Acker takes the helm against the backdrop of change at MSD, with a new global CEO and the abandonment of the company’s COVID-19 vaccine projects.…

Europe Jasper Kunow, MSD’s managing director for Central Eastern Europe, outlines the threat that cancer still poses to Europe, the challenges of enacting the EU’s Beating Cancer Plan across the CEE region, and how policymakers and payers can help overcome them   “In 2020, while we were all fighting against the…

Switzerland In February 2020, US giant MSD announced the launch of a new site in Zurich specialising in R&D, data management, and commercialisation, foregrounding the company’s commitment to Switzerland. MSD employs over 1000 people in Switzerland across five sites in local, regional, and global functions, engages in 25 in-country clinical trials…

Singapore Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and medtech multinationals, as well as domestic start-ups, have based regional functions in the clean, English speaking, and well-developed city-state with…

Singapore As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other markets. This situation keeps the Health Sciences Authority (HSA) – the country’s regulatory body – extremely busy. While challenges, including…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Singapore MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more resilient, agile, and digitally-focused affiliate; and why increased levels of public-private collaboration in the region are vital to building a…